• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 4th October 2011

Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing

Join OHE at ISPOR to discuss multiple criteria decision analysis, value based pricing, risk sharing, post-approval data collection and other key topics in HTA and health care decision making. The 14th Annual European Congress of the International Society for Pharmacoeconomics…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Profs Adrian Towse and Nancy Devlin

Join OHE at ISPOR to discuss multiple criteria decision analysis, value based pricing, risk sharing, post-approval data collection and other key topics in HTA and health care decision making.

The 14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will be held in Madrid on 5-8 November.

Profs Adrian Towse and Nancy Devlin Profs Towse and Devlin

 

OHE’s Nancy Devlin is the workshop committee co-chair for the Congress. Nancy also will be involved in two presentations that address the potential for using multi-criteria decision analysis (MCDA) as an aid in decision making about the use of new health care technologies. Both build on OHE’s research, published in its 2011 primer on MCDA.

At the workshop on ‘Multiple Criteria Decision Analyses for Health Technology Assessment’, Nancy will present the various methods and approaches to MCDA and how these might be used to more explicating incorporate cost effectiveness and other considerations into decision processes.  Nancy will be the moderator for an issues panel that will debate the topic ‘Multi-Criteria Decision Analysis: An Appropriate Framework for Decision Making about New Medical Technologies?’ Panellists will include Mark Sculpher, University of York; Stuart Peacock, University of British Columbia; and Carole Longson, NICE.

Adrian Towse is a speaker at the first plenary session, ‘Pros and Cons of a Centralized European Pricing and Reimbursement Agency,’ moderated by Mark Schulpher, University of York, and including also Hans-Georg Eichler, EMA. Should an agency similar in structure to EMA be established with a centralized procedure for pricing and reimbursement? Should this be a decision making agency or one that only undertakes health technology assessment?  If the latter, what forms of evaluation should be included?

Adrian is leading two other sessions and is a panellist on another. ‘Prospective Observational Studies for Newly Launched Drugs to Assess Relative Effectiveness’, focuses on how best to ensure the accuracy of data collected shortly after a new drug appears on the market.  Participants include Sebastian Schneeweiss, Harvard Medical School; Mark Cziraky, HealthCore; and Wim Goettsch, EUnetHTA.

Again focusing on data collecting after marketing commences, Adrian will moderate ‘Developing Good Research Practices for Performance-Based Risk Sharing’.  The discussion will address the development of ‘good practice’ standards to be applied in performance-based risk-sharing arrangements, including the design, implementation, and evaluation of such an arrangement.  Presented by the ISPOR Performance-Based Risk-Sharing Arrangements Good Research Practices Task Force, the panelists include Lou Garrison, University of Washington; Jens Grueger, Pfizer; Gerard de Pouvourville, the ESSEC Business School; and J.L. (Hans) Severens, Erasmus University Rotterdam.

The OHE has been very involved in issues surrounding value-based pricing, which will become mandatory for all prescription drugs newly marketed in the UK beginning in 2014.  Adrian will be a panelist in the session ‘Value Based Pricing: What Will It Mean in Practice?’  The panel will address a number of practical challenges that will arise from implementing VBP. The panel moderator is John Brazier, University of Sheffield; the other panelists are Karl Claxton, University of York and Jens Grueger, Pfizer.

With Lou Garrison and Josh Carlson of the University of Washington, Adrian will be presenting an intermediate-level short course, ‘Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products’.  Both payers and producers of medical products show a significant and growing interest in payment schemes that involve elements of ‘pay-for-performance’ or ‘risk-sharing’.  Despite their intrinsic appeal, barriers to implementation are substantial. The course covers both theory and practice, including several examples of performance-based schemes from Europe, the United States, and Australia.  An interactive session using a hypothetical case study will illustrate a systematic approach to weighing applicability and feasibility.  

  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
Danzon_Patricia_1305 (1)
  • News
  • June 2020

Victor R. Fuchs Award for 2020 Goes to Patricia Danzon

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!